BerGenBio

Share Issue/Capital Change • Nov 17, 2017

increase ofcapital

BerGenBio ASA: Exercise ofemployee share options and

Bergen, Norway, 17 November 2017 – The Board of Directors in BerGenBio ASA's (the "Company") (OSE: BGBIO) has, to fulfil the Company's obligations under the option agreements, resolved to increase the Company's share capital by minimum NOK 0,10 and maximum NOK 21,500 by issuance ofminimum 1 and maximum 215,000 new shares. The new shares shall be subscribed for by the employees that wish and are entitled to exercise options in accordance with the Company's option scheme. The subscription price shall be in accordance with the prevailing option price pursuant to the Company´s option scheme, ie NOK 5.65 – NOK 16.01 per share. The shares shall be subscribed for in a separate subscription document in the period from 18. November 2017 and up to and including 30. November 2017. -End- Contacts Richard Godfrey CEO, BerGenBio ASA +47 917 86 304 Tom Henrik Sundby Finance Director, BerGenBio ASA tom.sundby@bergenbio.com +47 477 54 415 Forward looking statements This announcement may contain forward-looking statements, which as such are nothistorical facts, but are based upon various assumptions, many ofwhich are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from theexpectations expressed orimplied in this announcement by such forward-looking

statements This information is subject to the disclosure requirements pursuant to section 5-12 ofthe Norwegian Securities Trading Act.